Related Experiment Video

Updated: Jun 8, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

Prevalence of CYP450 gene variations in patients with type 2 diabetes

A Weise1, S Prause, M Eidens

  • 1IKFE--Institute for Clinical Research and Development, Mainz, Germany. alexander.weise@pharmgenomics.de

Clinical Laboratory
|September 23, 2010
PubMed
Abstract

Insights

Type 2 diabetes may be linked to a specific gene mutation, CYP2C8*4. This finding suggests potential impacts on drug metabolism and treatment choices for diabetic patients, warranting further research.

Area of Science:

  • Pharmacogenomics
  • Metabolic Disorders
  • Drug Metabolism

Background:

  • Drug degradation in the body relies on detoxification pathways, which can be altered by genetic mutations.
  • The efficiency of these pathways can be influenced by genetic variations, impacting drug efficacy and safety.

Purpose of the Study:

  • To investigate the potential association between Type 2 diabetes and mutations in key CYP450 isoenzyme family members.
  • To explore the prevalence of specific genetic mutations in CYP2C8, CYP2C9, CYP2C19, CYP2D6, and PPARgamma in Type 2 diabetic patients compared to non-diabetic individuals.

Main Methods:

  • Genomic DNA was isolated from blood samples of 203 Caucasian subjects (101 with Type 2 diabetes, 102 controls).
  • Mutation analysis was performed using real-time PCR for CYP2C8 (*2/*3/*4), CYP2C9 (*2/*3), CYP2C19 (*2/*3), CYP2D6 (*3/*4/*5/*6), and PPARgamma (P12A).

Main Results:

  • Genotyping revealed a significantly higher prevalence of the CYP2C8*4 mutation in the Type 2 diabetes group (15% vs. 2%, p < 0.05).
  • No significant differences in allele frequencies were observed for other investigated mutations (CYP2C8*2, CYP2C8*3, all CYP2C9, CYP2C19, CYP2D6, and PPARgamma P12A) between the groups.

Conclusions:

  • This pilot study identified an increased prevalence of the CYP2C8*4 mutation in patients with Type 2 diabetes.
  • This finding suggests a potential impact on drug degradation and efficacy, possibly influencing the selection of anti-diabetic medications.
  • Further research is required to validate these preliminary results and elucidate their clinical significance.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...